The concentrations of NfL and GFAP in peripheral blood samples from patients with varying degrees of nervous system diseases were analyzed to investigate changes in their levels across different stages of disease progression, to evaluate their potential as biomarkers for AD, and to assess the diagnostic value and combined diagnostic value of blood NfL and GFAP for AD. This evidence concerns the gene NEFL and nervous system disorder.